Bank of Japan keeps interest rates steady at 0.25%

The Bank of Japan held steady its interest rates on Thursday, opting to observe wage growth and inflation trends. The decision, widely anticipated, maintains the short-term policy rate at -0.1%. Governor Kazuo Ueda will elaborate on this decision and the findings of a policy review examining 25 years of deflation-fighting strategies, marking a potential shift away from extensive stimulus.

Jungle Camps IPO listing today. Check GMP to know listing potential

Jungle Camps India shares are set to debut on the BSE SME platform Tuesday with a grey market premium of Rs 60, indicating a potential 83% listing premium. The IPO, which was oversubscribed 490 times, offered 40.86 lakh fresh equity shares. The company operates four award-winning eco-friendly resorts in central India, focusing on luxury and conservation-based tourism.

EMS segment picking up; Dixon top pick: Arafat Saiyed

Dixon Technologies, a leading electronics manufacturer, dominates the Indian smartphone market, partnering with major brands like Vivo, expanding its presence in the Android ecosystem. The company aims to increase its market share by focusing on higher-volume production and securing larger orders from existing clients. Analysts remain optimistic about Dixon’s growth prospects, particularly in the mobile phone segment.

Stocks to buy today: ITC, ICICI Bank among top 9 trading ideas for 16 December 2024

The Indian market is expected to consolidate on December 16, 2024, amid mixed global cues. India VIX indicates reduced investor anxiety. Market sentiment appears neutral to slightly bullish, with balanced call and put writing. Key resistance and support levels are 25,000 and 24,500, respectively. Experts recommend stocks like ITC, ICICI Bank, and RIL for short-term trading opportunities.

Lupin shares in focus on acquisition of 3 anti-diabetes trademarks to strengthen diabetes portfolio

Lupin has acquired the anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim to bolster its diabetes portfolio in India. The transfer will be complete by March next year. Lupin has been co-marketing these drugs since 2016 and 2018, respectively. This acquisition strengthens Lupin’s commitment to providing affordable diabetes medications.